PSMA scan changes after starting hormone therapy for prostate cancer
Part of Cancer clinical trials.
This study looks at how a prostate-specific scan marker (PSMA) changes after you start or continue hormone therapy. It may help doctors better understand who responds and how quickly prostate cancer biology shifts during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can sign consent before any study steps
- You have confirmed prostate cancer (prostate adenocarcinoma)
- Your PSMA PET scan shows prostate cancer “uptake” (signal) at the start
- You are starting planned hormone therapy within 8 weeks of the first PSMA PET
- You can be expected to live more than 3 months
- You do not have certain problems that would stop you from following the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special scan (PSMA PET/CT) to see how well a new type of hormone therapy is working in men whose prostate cancer has spread to other parts of the body. The goal is to find out if the scan can help doctors track the cancer's response to treatment over time.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
This Phase 2 study tests using a special PET/CT scan (PSMA or FACBC) to guide treatment for prostate cancer that has come back after surgery and radiation. The goal is to see whether this scan-based approach can better target cancer in the prostate area (and help plan the right treatment).
This trial tests a new way to plan radiation for high-risk prostate cancer. Doctors will use a special PET scan (PSMA PET) to find the main tumor inside the prostate and give it a stronger dose of radiation, along with standard hormone therapy. This approach might improve outcomes for patients with aggressive disease.
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.